Locus Cell Co

Locus Cell Co Capital Expenditures

The Capital Expenditures (CapEx) of Locus Cell Co (6891.TWO) as of Oct 17, 2026 is -446.19 M TWD. In the previous year, Capital Expenditures (CapEx) was -86.26 M TWD — a change of 417.26% (lower).

Capital Expenditures

-446.19 MTWD

YoY

417.26%

Last updated:

Capital Expenditures (CapEx) of Locus Cell Co is 2024 -446.19 M TWD. Capital Expenditures (CapEx) of Locus Cell Co was 2023 -86.26 M TWD. It decreases by 417.26% lower compared to the previous year.

The Locus Cell Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2021
-1.62 M TWD
Jan 1, 2022
-24.25 M TWD
Jan 1, 2023
-86.26 M TWD
Jan 1, 2024
-446.19 M TWD
The Locus Cell Co Capital Expenditures history
YEARCapital ExpendituresYoY
-446.19 MTWD+417.26%
-86.26 MTWD+255.70%
-24.25 MTWD+1,396.98%
-1.62 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Locus Cell Co Stock analysis

What does Locus Cell Co do? Locus Cell Co Ltd is a company based in Taipei, Taiwan, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company has 32 employees and went public on April 28, 2022. Its primary business involves the entrusted development and manufacturing of cell therapy-related products. Locus Cell Co Ltd utilizes a pilot facility compliant with Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP). The company provides services including process development and scale-up for cell therapy products, analytical method development and validation, clinical GMP manufacturing for trials, and stability testing. It is anticipated to offer services for various cell therapy applications, such as tissue engineering, CAR-T, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs). The company's website is http://www.locus-cell.com/. Locus Cell Co Ltd focuses on contract development and manufacturing organization (CDMO) services for cell therapy products, aiming to support the advancement of innovative therapies through its specialized GMP-compliant facility and technical expertise in cell therapy processes. Locus Cell Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Locus Cell Co stock

Capital Expenditures (CapEx) of Locus Cell Co is -446.19 M TWD in 2024.

Capital Expenditures (CapEx) of Locus Cell Co changed from -86.26 M TWD to -446.19 M TWD, representing a 417.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Locus Cell Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Locus Cell Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Locus Cell Co

All Key Metrics — Locus Cell Co